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Abstract 
Background: Lymphocyte expansion and true lymphocytosis are commonly observed in the everyday clinical 
practice. The meaning of such phenomenon is often poorly understood so that discrimination between benign 
and malignant lymphocytosis remains difficult to establish. This is mainly true when lymphocytosis rises in patients 
affected by immune-mediated chronic inflammatory diseases under immunosuppressive treatment, conditions 
potentially associated with lymphomagenesis. In this brief report the development of mild T CD4pos lymphocytosis in 
a group of patients with chronic arthritis under anti-TNF-α treatment is described.
Methods: Two hundred eight rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients have been evaluated 
longitudinally for at least 1-year before and 2-years after anti-TNF-α therapy introduction for the possible appearance 
of a lymphocyte expansion. In patients who developed lymphocyte expansion, T, B and NK cells were analysed.
Results: Twenty-five out of 208 (12%) subjects developed a mild T CD4pos lymphocytosis, during anti-TNF-α therapy, 
which reverted after its interruption. Higher lymphocyte count, more frequent use of steroids and shorter disease 
duration, before biological therapy start, have emerged as risk factors for lymphocytosis development.
Conclusions: This is the first longitudinal cohort study evaluating the onset of lymphocytosis in RA and PsA patients 
under anti-TNF-α treatment and its possible clinical relevance. A mild T CD4pos lymphocytosis has been observed 
in 12% of RA and PsA patients probably related to anti-TNF-α treatment as previously reported by anecdotal cases. 
Patients with higher baseline lymphocyte count, use of steroids and shorter disease duration before the introduction 
of biologic therapy, seem to be prone to develop this laboratory reversible abnormality.
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Background
Lymphocyte expansion and true lymphocytosis are com-
monly features in the everyday clinical practice. The 
meaning of such phenomenon is frequently poorly clear, 
so that discrimination between benign and malignant 
lymphocytosis is often hard to establish. Thus, the search 
for markers helping in such discrimination is highly 
warranted. This is mainly felt when lymphocyte abnor-
malities arise during the course of an immune-mediated 
chronic inflammatory disease, such as rheumatoid arthri-
tis (RA) and psoriatic arthritis (PsA) under immunosup-
pressive treatment, all conditions which predispose to 
lymphomagenesis. Lymphocyte expansion may roughly 
be divided into either reactive, reversible and benign 
phenomenon or a malignant lymphoproliferative, irre-
versible, disorder. Despite the causes of these abnormali-
ties not always come to light, infections are frequently 
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involved as promoting factor. Infectious agents gener-
ally induce reactive lymphocyte expansion, but some of 
them, including Epstein Barr Virus (EBV) or Kaposi’s 
Sarcoma Herpesvirus (KSHV), Human T lymphotropic 
virus 1 (HTLV1), Human immune deficiency virus 
(HIV), Hepatitis C virus (HCV) [1], Helicobacter pylori 
[2], Borrelia burgdorferi [3], Chlamydophila psittaci [4], 
Campylobacter jejuni [5], Achromobacter xylosoxidans 
[6], may be the direct cause of malignant lymphoprolif-
erative disorders. The diagnostic discrimination between 
the above reported conditions (mainly the recognition of 
the malignant lymphoproliferation) [7] is not always easy, 
because of the lack of reliable lymphomagenesis predic-
tive markers.
An increased risk for lymphoproliferative disorders 
has been reported in RA and PsA patients, with most 
of the studies indicating higher risk for Hodgkin’s and 
non-Hodgkin’s lymphomas (HL and NHL) [8–10]. Sev-
eral factors can be implicated in the onset or mainte-
nance of lymphomagenesis in RA and PsA, such as the 
genetic background and the persistent stimulation of T 
and B cells by unknown antigens. Continuous immune 
stimulation leads to chronic inflammation and imbalance 
between inflammatory and regulatory cytokines [11, 12]. 
Also immunosuppressive therapies might be associated 
to an increased risk of lymphoma [13]. Increased malig-
nancy rate has been initially reported, in both diseases, in 
association to anti-TNF-α therapy, but this observation is 
still controversial because data has not been confirmed 
by recent meta-analyses [14–18]. To date, four case 
reports of either T CD4pos or CD8pos lymphocytosis with 
an immunophenotype of large granular lymphocytes 
(LGL) [19, 20] and one case of T CD4pos lymphocyte pol-
yclonal expansion [21] in RA patients under anti-TNF-α 
therapy have been described.
In the daily clinical activity we too have observed 
lymphocyte expansion in RA and PsA patients under 
immunosuppressive therapy. These patients have been 
therefore systematically analysed, in order to possibly 
infer the clinical meaning of such observation.
Methods
Two hundred eight subjects (140 RA and 68 PsA), poorly 
responding to methotrexate (Mtx) thus even receiving an 
anti-TNF-α agent, have been followed-up for the level 
of peripheral blood lymphocytes. Lymphocytosis was 
defined as a number of circulating lymphocytes ≥3500/
µl for at least 3  months [22–24]. Patients have been 
selected among those attending S. Andrea University 
Hospital Immuno-Rheumatology outpatient clinic from 
December 2010 to November 2015. Patients have been 
evaluated longitudinally for at least 1-year before and 
2-years after addition of biologic therapy, the influence 
of which could therefore be analysed in every patient, 
who served as control of himself. In patients with circu-
lating lymphocytes ≥3500/µl, peripheral blood (PB) was 
collected and lymphocyte subpopulations (total T cells 
[CD3pos], T helper [CD3posCD4posCD45pos], T cytotoxic 
[CD3posCD8posCD45pos], natural killer [CD16posCD-
56posCD45pos] and B cells [CD19posCD45pos]) were ana-
lysed using a standard protocol based on four-color 
immune-fluorescence flow-cytometer, as previously 
described [25]. In brief, BD multitest IMK kit with tri-
count tubes (BD biosciences) consisting of a four-color 
direct immunofluorescence reagent kit for FACS Canto 
II (BD biosciences) to determine mature human lympho-
cyte subsets in erythrocyte-lysed whole blood samples 
was used. The following monoclonal antibodies were pre-
sent in different combinations: FITC-labeled CD3, PE-
labeled CD8, PerCP-labeled CD45, APC-labeled CD4, 
PE-labeled CD16 and FITC-labeled CD56, APC-labeled 
CD19. Twenty thousand lymphocytes were tested for 
each sample. Data was analysed using a dedicated Canto 
II software.
Data was analysed using StatView statistical program 
for MacIntosh (StatView Software, San Diego, CA) 
and P value was determined with the paired Student’s 
t test. P values <0.05 were considered to be statistically 
significant.
Results
None of the 208 total patients developed lymphocyto-
sis during the 1-year treatment with Mtx (7.5–15  mg/
weekly)  ±  low dose steroids (<7.5  mg of prednisone/
daily). After start of anti-TNF-α treatment, in combina-
tion with preexisting synthetic immunosuppressants, 
25/208 (12%, 15 RA and 10 PsA, Group A) showed a 
significant increase in the lymphocyte count leading to 
a mild lymphocytosis [from 2800 to 4000 mean cells/µl 
(mean ratio of increase 1.44); P < 0.001; Fig. 1], whereas in 
the remaining 183 patients (Group B) lymphocyte count 
remained substantially stable (from 1866 to 2012 [mean 
ratio of increase 1.1]) (Table  1). Of note, no changes in 
immunosuppressive therapy other than biologic introduc-
tion were adopted in the group A patients at least in the 
3 months before the lymphocytosis onset.
The median time between the beginning of the biologi-
cal therapy and the development of lymphocytosis was 
9  months (range 2–24  months; 16/25 patients within 
6  months). No concomitant clinical signs of infection 
were present nor serological tests for hepatitis B, C, cyto-
megalovirus and EBV or screening tests for tuberculosis 
were positive.
One hundred nine patients received etanercept (Etn), 
60 adalimumab (Ada), 19 infliximab (Ifx), 15 golimumab 
(Gol) and 5 certolizumab pegol (Ctz). Eleven out of 109 
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(10%) under Etn, 7/60 (11.7%) under Ada, 4/19 (21%) 
under Ifx and 3/15 (20%) patients under Gol developed 
lymphocyte expansion (no significant differences).
A comparison of the main clinical and demographic 
characteristics of group A and B before starting anti-
TNF-α treatment was performed, aiming at identi-
fying possible distinctive parameters to be used as 
predictive markers for lymphocytosis. The analysis showed 
that group A patients had a significantly shorter disease 
duration before the beginning of the biological therapy 
and more frequent use of steroids (Table 1). Furthermore, 
group A patients presented physiological, but significantly 
higher, lymphocyte count as compared to group B (2800 
vs 1866 cells/µl; P  <  0.001). The disease activity score 
(DAS) instead did not show any significant difference 
between the two groups. The analysis of PB lymphocyte 
subsets revealed that B and NK cells were not the cause 
of the lymphocyte expansion. In fact, the distribution 
of these two lymphocyte subpopulations was at the low-
est limit of the normal range (9.6% ±  1.4 and 8% ±  2.3; 
normal 10–16 and 8–14% respectively). In contrast, an 
increase in the mean percentage and number of the total 
CD3pos cells (79.5 ± 5.6%; 3120 ± 220/μl) and CD3posCD-
4pos cells (50.8 ± 4.4%; 1962 ± 190/μl) accompanied by a 
mild reduction in the CD3posCD8pos T cells (27.2 ± 1.2%; 
1028 ± 60/μl) was observed, with a consequent CD4/CD8 
ratio at the upper limit of the normal range. In order to 
gain more insights on this T cell expansion, a TCRγ gene 
rearrangement analysis was performed in all 25 patients. 
In five individuals the predominance of a monoclonal 
peak of about 160 bp was observed. Following hematolo-
gist suggestion a total lymph nodes ultrasonography was 
performed. Although the analysis did not reveal any sign 
of lymph node or spleen enlargement, treatment with 
biologic therapy was interrupted as precautionary meas-
ure. Within 3  months after anti-TNF-α therapy suspen-
sion, total lymphocyte count returned to normal values 
(from 4134 ± 506 to 3168 ± 203/µl; P < 0.008, Fig. 1) and 
remained stable over 9 further months of follow-up. In one 
of these patients, in which a rechallenge with biologic ther-
apy was necessary as a consequence of RA flare up, it was 
possible to observe the reappearance of lymphocytosis. 
In the group A patients, who continued biologic therapy, 
lymphocyte count remained stably above normal values 
during the 1-year period of follow-up (Fig. 1).
Discussion
A group of RA and PsA patients who developed a mild 
TCD4pos lymphocytosis during anti-TNF-α treatment is 
here described. Higher lymphocyte count, use of ster-
oids in association to Mtx and shorter disease duration, 
before the beginning of the biologic therapy, were associ-
ated with the onset of TCD4pos lymphocytosis. Consider-
ing that DAS was similar in the two groups of patients, 
the significant higher lymphocyte count observed in the 
group A may be more reliable expression than DAS of 
active/aggressive disease, as documented by the more 
frequent use of steroids and significant shorter disease 
duration before starting biologic therapy.
In the absence of clear guidelines for the management of 
lymphocytosis in RA and PsA patients under anti-TNF-α 
therapy, the biologic therapy was interrupted in the five 
patients presenting a lymphocytosis and a monoclonal 
TCRγ chain repertoire. Within 3  months following the 
interruption of TNF-α inhibitor a significant decrease 
in the lymphocytes level, until physiological values, was 
observed, whereas in the patients who did not interrupt 
biologic therapy the number of lymphocytes remained sta-
ble (Fig. 1). In one of these patients, in which a rechallenge 
with biologic therapy was necessary as a consequence 
of RA flare up, it was possible to observe the reappear-
ance of lymphocytosis. Analysis of the data with Naranjo 
algorithm gave a probability score result for causality of 
6 thus indicating a probable anti-TNF-α induced event 
[26]. Despite the persistence of lymphocyte expansion and 
the probable link with anti-TNF-α agents, as previously 
reported in anecdotal cases (19–21), none of the patients 
developed clinical or laboratory signs of progression 
toward malignancy at 1-year follow-up. Consequently, 
this haematologic abnormality appears as a benign revers-
ible drug-related laboratory finding other than a seri-
ous adverse event, at least for the observation period. In 
RA patients, the risk of developing hematologic tumors 
is higher than in the healthy population [27]. In particu-
lar large granular lymphocytosis is frequently associated 
with RA and other autoimmune diseases [28]. Reversible 
T lymphoproliferation in RA patients under anti-TNF-α 
Fig. 1 Total lymphocyte count (cells/µl) in 25 patients with lympho-
cytosis throughout the follow-up. Dashed line indicates the upper 
limit of normal lymphocyte count. T0 Methotrexate ± steroids 
therapy; T1 Addition of anti-TNF-a therapy; T2 Peak of lymphocytes 
level (bold black lines identify the patients in whom anti-TNF-a therapy 
was interrupted); T3 Three months from T2; T4 Twelve months from T2
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therapy has been occasionally described in case reports. 
Sometimes the number of CD8pos T cells is altered [20], 
but more frequently CD4pos is the main T cell subset to be 
affected. The lymphocyte expansion may be either mono-
clonal [19] or polyclonal [21]. Reversible lymphoprolifera-
tion has also been described as a consequence of CMV 
reactivation [29]. However, the cause for reversible lym-
phoproliferation in these patients has not yet been identi-
fied, it is known that TNF-α can limit T cell expansion and 
induce apoptosis in both naïve and memory T cells [30], 
consequently TNF-α blocking agents may lead to a dys-
regulation of these biologic mechanisms, thus resulting 
in T cell expansion and/or prolonged survival. Moreover, 
in addition to anti-TNF-α biologic treatment, the role of 
steroids in promoting lymphoproliferation can not be for-
gotten. Recent studies have demonstrated that steroids are 
able to significantly reduce circulating T regulatory cells 
[31], thus adding fuel to the hypothesis that immunosup-
pressive therapy may in certain conditions induce T cell 
expansion. The higher risk of lymphoma in RA patients 
treated with TNF-α inhibitors has been suggested but not 
clearly demonstrated. Several factors may hinder a defini-
tive correlation between anti-TNF-α therapy and lym-
phoma development, among which the selection of the 
population enrolled in different studies or national reg-
istries and the inter individual variability of the immune 
system exposed to TNF-α. In fact, being a double sword 
tool, TNF-α may play a defensive role by stimulating NK 
and cytotoxic T lymphocytes, but can also be “offensive” 
acting as mediator of cancer development through chronic 
inflammation promotion [13]. Thus, in theory, TNF-α 
antagonists may either promote or inhibit cancer growth 
[32]. The onset of B-cell lineage lymphomas and hepato-
splenic T cell lymphoma (HSTCL) has been observed in 
patients with Crohn’s disease who received anti-TNF-α 
agents mainly in association to thiopurines [33–35]. Of 
note, in patients with psoriasis, an absolute lymphocyto-
sis associated to γδ T cell lymphoma after treatment with 
anti-TNF-α has been observed [36, 37].
Conclusions
This is the first longitudinal cohort study evaluating the 
onset of lymphocytosis in RA and PsA patients under 
anti-TNF-α treatment and its possible clinical relevance. 
A mild T CD4pos lymphocytosis has been observed in a 
not negligible percentage of RA and PsA patients prob-
ably related to anti-TNF-α treatment as previously 
reported by anecdotal cases. Higher lymphocyte count, 
use of steroids and shorter disease duration before the 
introduction of biologic therapy, have come to light as 
risk factors for lymphocytosis development. Despite 
the persistence of lymphocyte expansion and its prob-
able link with anti-TNF-α agents, none of the patients 
developed clinical or laboratory signs of progression 
toward malignancy at 1-year follow-up. Although current 
data are reassuring and suggest that this alteration have 
a benign trend, a longer follow-up and genetically analy-
sis of these patients is suitable in order to gain a deeper 
insight of this phenomenon.
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